Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: prophet_often who wrote (12)	1/10/2001 1:57:07 PM
From: LTK007	Respond to of 897

i have been checking IVGN,and i concur--and just heard a biotech analysts say "tools were in last year,tools are out this year now the street want drug product,not tool kits." (not verbatim)--we will see.max

To: prophet_often who wrote (12)	1/10/2001 3:13:38 PM
From: Biomaven	Read Replies (1) \| Respond to of 897

IVGN This is a low margin business. The profile lists their profit margin at 0.6% and their operating marging at 1.8%. Am I missing something here? I can't believe people are buying (or shorting) stocks based on the numbers in some "profile." IVGN just completed a very large merger, and this considerably distorts their current numbers because of purchase accounting and other factors. Historically, their gross margins have been around 60%, with a revenue CAGR over the last 5 years of around 30%. There's likely to be some short-term pressure on margins because of the merger, but a return to the old numbers is likely after a few quarters. Revenue growth over the next several years should continue very strong. I still own some IVGN I received in the LTEK merger. Peter